

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-145)

OLVIMULOGENE NANIVACIREPVEC

PRONUNCIATION

ol" vi mul' oh jeen nan" i vas i rep' vek

THERAPEUTIC CLAIM

Antineoplastic


DESCRIPTION

DNA (recombinant vaccinia virus strain LIVP clone GL-ONC1)

Recombinant replication-competent oncolytic vaccinia virus VACV (LIVP strain) comprising insertion of the *ruc-gfp*, beta-galactosidase (*LacZ*) and beta-blucuronidase (*gusA*) reporter genes into the F14.5L, J2R (thymidine kinase) and A56R (hemagglutinin) loci, respectively.

STRUCTURAL FORMULA

Schematic Map of GL-ONC1



Abbreviations: *gusA*, *E. coli*  $\beta$ -glucuronidase gene; *lacZ*, *E. coli*  $\beta$ -galactosidase gene; *ruc-gfp*, fusion of *Renilla* luciferase cDNA and green fluorescent protein cDNA; *TFR*, cDNA of human transferrin receptor, which was inserted in reverse orientation downstream of promoter; p11, vaccinia virus strain Western Reserve (WR) late p11 promoter; pE/L, synthetic early/late promoter; p7.5, vaccinia virus WR early/late promoter.

TRADEMARK

None as yet

SPONSOR

Genelux Corporation

CODE DESIGNATION

GL-ONC1

CAS REGISTRY NUMBER

1473430-36-2

UNII

CF19SF72O5

WHO NUMBER

11165

SCS